Pharmacogn Mag. 2015 Oct;11:S427-33. doi: 10.4103/0973-1296.168982.
Toxicological Evaluation of Emblica officinalis Fruit Extract and its Anti-inflammatory and Free Radical Scavenging Properties.
Pharmacognosy magazine
Sushil Kumar Middha, Arvind Kumar Goyal, Prakash Lokesh, Varsha Yardi, Lavanya Mojamdar, Deepthi Sudhir Keni, Dinesh Babu, Talambedu Usha
Affiliations
Affiliations
- Department of Biotechnology, Maharani Lakshmi Ammanni College for Women, Malleswarm, Bengaluru, Karnataka, India.
- Department of Biotechnology, Bamboo Technology, Bodoland University, Kokrajhar, BTAD, Assam, India.
- Department of Biochemistry, CPGS, Jain College, Bengaluru, Karnataka, India.
- Department of Biochemistry, Maharani Lakshmi Ammanni College for Women, Malleswarm, Bengaluru, Karnataka, India.
- Department of Biotechnology, Sapthagiri College of Engineering, Bengaluru, Karnataka, India.
- Heymans Institute of Pharmacology, Ghent University, Belgium.
PMID: 26929577
PMCID: PMC4745213 DOI: 10.4103/0973-1296.168982
Abstract
BACKGROUND: Emblica officinalis (Euphorbiaceae), popularly known as Indian gooseberry or "Amla" in India, is used in Ayurveda as "rejuvenating herb" since ancient times.
OBJECTIVE: This study was carried out to estimate toxicity, anti-inflammatory, and antioxidative activities of the methanolic extract of Emblica officinalis fruit (MEO) in an animal model.
MATERIALS AND METHODS: Antioxidative property of MEO was assessed by in vitro assays such as phosphomolybdenum assay (total antioxidant capacity), free radical scavenging assays 1,1-diphenyl-2-picrylhydrazyl and 2,2'-azino-bis and 3-ethylbenzthiazoline-6-sulphonic acid (DPPH and ABTS method) and lipid peroxidation assay (LPO). The anti-inflammatory property was evaluated by carrageenan-induced acute inflammation in rats by measuring rat paw volume at different time intervals and toxicological analysis using mice.
RESULTS AND DISCUSSION: High performance liquid chromatography studies revealed the presence of gallic acid (2.10%), mucic acid (4.90%), ellagic acid (2.10%), quercetin (28.00%), rutin (3.89%), and β-glucogallin (1.46%). MEO showed highest antioxidant activities by using DPPH (17.33-89.00%), ABTS (23.03-94.16%), nitric oxide scavenging activity (12.94-70.16%), LPO (56.54%), and phosphomolybdenum assay (142 ± 6.09 μg/ml). The LD50 was found to be approximately 1125 mg/kg (p.o). High dose of MEO showed significant reduction (72.71%) in the inflammation after 4 h of treatment, which was comparable to diclofenac (10 mg/kg) (61.57%) treated group. Significant reduction (P < 0.05) in the inflammatory cytokine (interleukin-1β and tumor necrosis factor-α) markers were also observed (57.25% and 35.41%, respectively) in serum of MEO treated animals as compared to control.
CONCLUSION: Taken together, phenolic compounds of MEO may serve as a potential herbal drug for amelioration of acute inflammation due to their modulatory action on free radicals.
SUMMARY: The methanolic extract of Emblica officinalis fruit (MEO) has potent antioxidant activity as assessed by DPPH, ABTS and LPO assaysMEO has potent anti-inflammatory activity in carrageenan induced paw edema modelThe phenolic compounds of MEO might be a potential herbal drug for amelioration of acute inflammation. Abbreviations used: ROS, reactive oxygen species; RNS, reactive nitrogen species, LPO, lipid peroxidation, NO, nitric oxide, IL, interleukin; TNF α tumor necrosis factor alpha; NSAIDs, nonsteroidal anti inflammatory drugs; AA, ascorbic acid; MEO, methanolic extract of Emblica officinalis fruit; ABTS+; 2,2' azino bis 3 ethylbenzthiazoline 6 sulphonic acid; DPPH, 1,1 diphenyl 2 picrylhydrazyl; HPLC, high performance liquid chromatography; MDA, malondialdehyde; DMSO, dimethyl sulphoxide; ELISA, enzyme linked immunosorbent assay.
Keywords: 1-diphenyl-2-picrylhydrazyl; Emblica officinalis; acute inflammation; amla; antioxidant; high performance liquid chromatography
References
- Anal Biochem. 1999 May 1;269(2):337-41 - PubMed
- Biomed Pharmacother. 2002 Jul;56(5):215-22 - PubMed
- Proc Soc Exp Biol Med. 1962 Dec;111:544-7 - PubMed
- Curr Vasc Pharmacol. 2003 Jun;1(2):135-56 - PubMed
- Eur J Immunol. 2005 Feb;35(2):584-92 - PubMed
- Clin Med Res. 2007 Mar;5(1):19-34 - PubMed
- J Sep Sci. 2007 Jun;30(9):1250-4 - PubMed
- Bioinformation. 2009 Aug 26;4(2):78-9 - PubMed
- Inflammopharmacology. 2011 Dec;19(6):327-34 - PubMed
- Eur Rev Med Pharmacol Sci. 2011 Apr;15(4):427-35 - PubMed
- Indian J Clin Biochem. 2010 Oct;25(4):419-24 - PubMed
- Adv Pharmacol Sci. 2012;2012:862625 - PubMed
- Adv Pharmacol Sci. 2012;2012:245431 - PubMed
- PLoS One. 2012;7(9):e45227 - PubMed
- Evid Based Complement Alternat Med. 2013;2013:734824 - PubMed
- Afr J Tradit Complement Altern Med. 2011 Oct 02;9(1):138-52 - PubMed
- Adv Pharmacol Sci. 2013;2013:296236 - PubMed
- J Biosci. 2013 Nov;38(4):797-803 - PubMed
- ScientificWorldJournal. 2013 Dec 29;2013:162750 - PubMed
- Avicenna J Phytomed. 2013 Spring;3(2):112-25 - PubMed
- Int J Inflam. 2014;2014:178408 - PubMed
- Antioxidants (Basel). 2014 Dec 03;3(4):830-42 - PubMed
- Foods. 2013 Mar 13;2(1):90-99 - PubMed
- Anal Biochem. 1979 Jun;95(2):351-8 - PubMed
- Planta Med. 1994 Oct;60(5):395-9 - PubMed
- Clin Sci (Lond). 1993 Apr;84(4):407-12 - PubMed
Publication Types